Literature DB >> 18083105

The classical complement cascade mediates CNS synapse elimination.

Beth Stevens1, Nicola J Allen, Luis E Vazquez, Gareth R Howell, Karen S Christopherson, Navid Nouri, Kristina D Micheva, Adrienne K Mehalow, Andrew D Huberman, Benjamin Stafford, Alexander Sher, Alan M Litke, John D Lambris, Stephen J Smith, Simon W M John, Ben A Barres.   

Abstract

During development, the formation of mature neural circuits requires the selective elimination of inappropriate synaptic connections. Here we show that C1q, the initiating protein in the classical complement cascade, is expressed by postnatal neurons in response to immature astrocytes and is localized to synapses throughout the postnatal CNS and retina. Mice deficient in complement protein C1q or the downstream complement protein C3 exhibit large sustained defects in CNS synapse elimination, as shown by the failure of anatomical refinement of retinogeniculate connections and the retention of excess retinal innervation by lateral geniculate neurons. Neuronal C1q is normally downregulated in the adult CNS; however, in a mouse model of glaucoma, C1q becomes upregulated and synaptically relocalized in the adult retina early in the disease. These findings support a model in which unwanted synapses are tagged by complement for elimination and suggest that complement-mediated synapse elimination may become aberrantly reactivated in neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083105     DOI: 10.1016/j.cell.2007.10.036

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  1175 in total

Review 1.  Regulation of microglia by ionotropic glutamatergic and GABAergic neurotransmission.

Authors:  Wai T Wong; Minhua Wang; Wei Li
Journal:  Neuron Glia Biol       Date:  2011-12-14

2.  Glaucomatous tissue stress and the regulation of immune response through glial Toll-like receptor signaling.

Authors:  Cheng Luo; Xiangjun Yang; Angela D Kain; David W Powell; Markus H Kuehn; Gülgün Tezel
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

Review 3.  Microglia and astrocyte dysfunction in parkinson's disease.

Authors:  Tae-In Kam; Jared T Hinkle; Ted M Dawson; Valina L Dawson
Journal:  Neurobiol Dis       Date:  2020-07-28       Impact factor: 5.996

Review 4.  Microglia in Alzheimer's disease.

Authors:  Heela Sarlus; Michael T Heneka
Journal:  J Clin Invest       Date:  2017-09-01       Impact factor: 14.808

5.  Shotgun proteomics implicates extracellular matrix proteins and protease systems in neuronal development induced by astrocyte cholinergic stimulation.

Authors:  Nadia H Moore; Lucio G Costa; Scott A Shaffer; David R Goodlett; Marina Guizzetti
Journal:  J Neurochem       Date:  2008-12-10       Impact factor: 5.372

6.  Complement Targets Newborn Retinal Ganglion Cells for Phagocytic Elimination by Microglia.

Authors:  Sarah R Anderson; Jianmin Zhang; Michael R Steele; Cesar O Romero; Amanda G Kautzman; Dorothy P Schafer; Monica L Vetter
Journal:  J Neurosci       Date:  2019-01-15       Impact factor: 6.167

Review 7.  Multitasking Microglia and Alzheimer's Disease: Diversity, Tools and Therapeutic Targets.

Authors:  Alexandra Grubman; Katja M Kanninen; Tarja Malm
Journal:  J Mol Neurosci       Date:  2016-09-22       Impact factor: 3.444

8.  Fosb gene products contribute to excitotoxic microglial activation by regulating the expression of complement C5a receptors in microglia.

Authors:  Hiroko Nomaru; Kunihiko Sakumi; Atsuhisa Katogi; Yoshinori N Ohnishi; Kosuke Kajitani; Daisuke Tsuchimoto; Eric J Nestler; Yusaku Nakabeppu
Journal:  Glia       Date:  2014-04-25       Impact factor: 7.452

Review 9.  Stem Cell-Based Immunomodulation After Stroke: Effects on Brain Repair Processes.

Authors:  Marieke C S Boshuizen; Gary K Steinberg
Journal:  Stroke       Date:  2018-05-03       Impact factor: 7.914

10.  Axonal degeneration as a self-destructive defense mechanism against neurotropic virus infection.

Authors:  Ikuo Tsunoda
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.